Skip to content
IsraelNational.News
Menu
Israel
Entertain
Tech
Sports
World
Business
Science
Health
IsraelNational.News
Menu
Israel
Entertain
Tech
Sports
World
Business
Science
Health
immuno-oncology
ASCO GU: Merck, Eisai turn up the heat in kidney cancer with Keytruda-Lenvima survival data
Pembrolizumab / Ipilimumab Combo does not improve survival, showing higher toxicity in PD-L1 + NSCLC